Blog Coverage3D Systems and United Therapeutics Partner to Develop 3D Bioprinted Lungs

LONDON, UK / ACCESSWIRE / April 27, 2017 / Active Wall St. blog coverage looks at the headline from the manufacturer of 3D printer 3D Systems Corp. (NYSE: DDD) and Biotech Company United Therapeutics Corp. (NASDAQ: UTHR) as both companies announced on April 26, 2017, that they have entered into a multi-year collaboration and development agreement. The collaboration will see the combining of 3D Systems’ expertise in 3D printing and precision with United Therapeutics competence in regenerative medicine and organ manufacturing. Register with us now for your free membership and blog access at:

http://www.activewallst.com/register/

Today, AWS is promoting its blog coverage on DDD and UTHR. Get all of our free blog coverage and more by clicking on the link below:

http://www.activewallst.com/register/

Sharing his views on the collaboration agreement, Martine Rothblatt, Ph.D., Chairman and CEO of United Therapeutics said:

“Our partnership with 3D Systems is a major step forward in creating an unlimited supply of tolerable transplanted organs. By cellularizing scaffolds created with 3D Systems printers with a patient’s own cells, there will no longer be a need for immunosuppression and a vastly greater number of patients can extend their enjoyment of life through organ transplantation.”

Vyomesh Joshi, CEO of 3D Systems added:

“We believe bioprinting is a powerful opportunity and we are uniquely positioned with the broadest portfolio of technologies to partner with Companies of the calibre of United Therapeutics to provide healthcare solutions of the future.”

Details of the Agreement

The agreement will see 3D Systems joining hands with Lung Biotechnology PBC, an organ manufacturing and transplantation-focused subsidiary of United Therapeutics. The collaboration will focus on the development of 3D printing systems that can be used for solid-organ scaffolds. The project will initially start work on lung scaffolds.

3D Systems will focus on developing a printing system that will target collagen and other building block proteins as raw materials for scaffold. United Therapeutics will focus on cellularizing the scaffolds with patient-specific biological material, including use of re-differentiated stem cells.

The project will be based at 3D Systems’ new bioprinting lab at San Diego, California. The project will require the full utilization of 3D Systems technical capabilities as well as domain knowledge and expertise of professionals at Lung Biotechnology PBC.

United Therapeutics has been working on several technological alternatives for creating a supply of organs that can be easily transplanted in humans. The current project will be a marked attempt in this direction. Its subsidiary Lung Biotechnology PBC is a public benefit corporation is taking this goal forward and working personal regenerative medicine. It is focused on finding a solution to the acute shortage of transplantable lungs and other organs.

What is bioprinting?

Bioprinting is a new emerging technology, and is an offshoot of 3D printing. However, Bioprinting is more complicated than other 3D printing. Bioprinting is the three-dimensional printing of biological tissue and organs through the layering of living cells. Bioprinting helps to replicate human organs. The long-term goal is to create a whole organ. However, this technology is in its embryonic stage.

Bioprinting is being applied to regenerative medicine to address the need for tissues and organs that are suitable for transplantation. It is being used for generation and transplantation of several tissues, including multi-layered skin, bone, vascular grafts, tracheal splints, heart tissue, and cartilaginous structures.

About the Collaborators

3D Systems are the originators of 3D printing and manufacture a range of 3D products and services, including 3D printers, print materials, on-demand parts services and digital design tools. 3D Systems has spent over 30 years enabling professionals and Companies to optimize designs, transform workflows, bring innovative products to market, and drive new business models. These devices and services support advanced applications from product design in a factory to operating room. It has already established itself in the healthcare sector and its precision healthcare capabilities include simulation, Virtual Surgical Planning, and printing of medical and dental devices as well as patient-specific surgical instruments.

Silver Spring, Maryland based United Therapeutics is a biotechnology Company. It is focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions. Apart from Silver Spring the Company has additional facilities at Research Triangle Park, North Carolina and Chertsey, Surrey, UK and offices in Germany, Canada and China.

Stock Performance

At the closing bell, on Wednesday, April 26, 2017, 3D Systems’ stock climbed 1.80%, ending the trading session at $15.87. A total volume of 2.28 million shares were traded at the end of the day, which was higher than the 3-month average volume of 1.95 million shares. In the last month and previous six months, shares of the Company have surged 11.52% and 12.47%, respectively. Moreover, the stock surged 19.41% since the start of the year. At Wednesday’s closing price, the stock’s net capitalization stands at $1.79 billion.

At the close of trading session on Wednesday, April 26, 2017, United Therapeutics’ stock price fell 1.44% to end the day at $119.99. A total volume of 1.69 million shares were exchanged during the session, which was above the 3-month average volume of 618.59 thousand shares. The Company’s share price has advanced 7.33% and 2.16% in the last six months and past twelve months, respectively. Shares of the company have a PE ratio of 7.91. The stock currently has a market cap of $5.38 billion.

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com

Phone number: 1-858-257-3144

Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street

ReleaseID: 460777